ALAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Astera Labs is a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to deploy, and I would rate it as a buy. The stock has strong momentum, a powerful fundamental growth story, and meaningful analyst and hedge fund support. Even after the sharp recent run, the combination of strong AI networking demand, Nasdaq-100 inclusion, and continued product ramps makes it an attractive long-term accumulation candidate. Given the user scenario and impatience, this is a buy now rather than a wait-for-lower-entry situation.
ALAB is in a clear bullish trend. The moving averages are aligned positively with SMA_5 > SMA_20 > SMA_200, which confirms an uptrend. RSI_6 at 65.47 is elevated but not overbought enough to signal exhaustion. MACD histogram is negative at -1.629 but is contracting, which suggests downside momentum is fading rather than accelerating. Price at 373.03 is above the pivot of 339.914 and near resistance R1 at 366.413, with the next major upside level at R2 at 382.784. Overall, the chart shows strong trend continuation with some short-term consolidation risk after the recent surge.
The biggest catalyst is the Nasdaq-100 inclusion announced on 2026-06-12, which is typically supportive for demand and visibility. News also shows extremely strong Q1 results: revenue rose 93.5% year over year to $308.4 million, and the company launched the Scorpio X networking switch, expected to be its largest product this year. Management guided Q2 revenue midpoint to $360 million, and shares already reacted sharply higher on the earnings beat and raise. Analyst revisions have also been largely positive, with multiple target increases after the quarter. Hedge funds are buying aggressively, with buying up 678.70% over the last quarter.
The MACD is still negative on a short-term basis, indicating the stock may need time to digest gains. Insider trading is neutral, so there is no strong insider support signal. Also, the stock's recent move has been extremely strong, which may limit near-term upside compared with the long-term story.
Latest quarter: Q1 2026. Financially, Astera Labs posted strong growth, with revenue up 93.5% year over year to $308.4 million. The company also issued Q2 revenue guidance with a midpoint of $360 million, indicating continued strong momentum into the next quarter. The earnings commentary suggests broad-based product ramp strength across its AI connectivity portfolio, especially Scorpio, Aries, and Taurus, with additional growth expected from optical products in FY27.
Analyst sentiment is still mostly positive, but slightly more mixed after the run-up. Several firms raised price targets after Q1 results: Evercore to $297, RBC to $270, Needham to $260, Stifel to $260, Susquehanna to $230, Northland to $225, Barclays to $200, and Roth to $275. Most retain Buy/Outperform-style ratings, but TD Cowen is Hold and Northland recently downgraded to Market Perform due to valuation. Wall Street overall remains constructive on the growth outlook, but some pros are now more cautious because the stock has appreciated quickly and is trading at a demanding valuation.
